Loading patent…
AssigneeSividon Diagnostics GmbH
InventorsMathias Gehrmann, Karsten Weber, Ralf Kronenwett, Christoph Petry, Jan Christoph Brase
Estimating the term…
A method for predicting a response to and/or benefit of chemotherapy, including neoadjuvant chemotherapy, in a patient suffering from or at risk of developing recurrent neoplastic disease, in particular breast cancer, said method comprising the steps of: (a) determining in a tumor sample from said patient the RNA expression levels of the following 8 genes: UBE2C, RACGAP1, DHCR7, STC2, AZGP1, RBBP8, IL6ST, and MGP, indicative of a response to chemotherapy for a tumor, or (b) determining in a tumor sample from said patient the RNA expression levels of the following 8 genes: UBE2C, BIRC5, DHCR7, STC2, AZGP1, RBBP8, IL6ST, and MGP; indicative of a response to chemotherapy for a tumor (c) mathematically combining expression level values for the genes of the said set which values were determined in the tumor sample to yield a combined score, wherein said combined score is predicting said response and/or benefit of chemotherapy.
A method for predicting a response to and/or benefit of chemotherapy in a patient suffering from or at risk of developing recurrent neoplastic disease, said method comprising the steps of:
(canceled)
A computer program product stored on a data carrier or implemented on a diagnostic system, capable of outputting values representative of an expression level of a given gene, mathematically combining said values to yield a combined score, wherein said combined score is predictive of said response and/or benefit of chemotherapy.
Dependencies are inferred from the claim text.